Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023

Publisher Name :
Date: 17-Apr-2018
No. of pages: 109

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Scope of the Report:

This report focuses on the Drugs for Vulvovaginal Candidiasis in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

- Bayer

- Perrigo

- J & J

- Pfizer

- Bristol-Myers Squibb

- Effik

- Teva

- Sanofi

- Cisen Pharmaceutical

- Kingyork Group

Market Segment by Regions, regional analysis covers

- North America (United States, Canada and Mexico)

- Europe (Germany, France, UK, Russia and Italy)

- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

- South America (Brazil, Argentina, Colombia etc.)

- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

- Miconazole

- Clotrimazole

- Fluconazole

- Econazole

- Other

Market Segment by Applications, can be divided into

- Hospital & Clinic

- Pharmacy

There are 15 Chapters to deeply display the global Drugs for Vulvovaginal Candidiasis market.

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Drugs for Vulvovaginal Candidiasis, with sales, revenue, and price of Drugs for Vulvovaginal Candidiasis, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Drugs for Vulvovaginal Candidiasis Market 2018 Forecast to 2023

Table of Contents

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Miconazole
1.2.2 Clotrimazole
1.2.3 Fluconazole
1.2.4 Econazole
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital & Clinic
1.3.2 Pharmacy
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Perrigo
2.2.1 Business Overview
2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 J & J
2.3.1 Business Overview
2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Effik
2.6.1 Business Overview
2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva
2.7.1 Business Overview
2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cisen Pharmaceutical
2.9.1 Business Overview
2.9.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Kingyork Group
2.10.1 Business Overview
2.10.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Drugs for Vulvovaginal Candidiasis Market Competition, by Manufacturer
3.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
3.4.2 Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Drugs for Vulvovaginal Candidiasis Market Analysis by Regions
4.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2013-2018)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2013-2018)
4.2 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
5 North America Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
5.1.3 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.1.4 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.1.5 Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.2 North America Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
5.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
5.3 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
5.3.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
5.4 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
5.4.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
6 Europe Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
6.1 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
6.1.3 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.4 UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.5 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.6 Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.1.7 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.2 Europe Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
6.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
6.3 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
7.1.3 China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.4 Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.5 Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.6 India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
8 South America Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
8.1 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
8.1.1 South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
8.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
8.1.3 Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.1.4 Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.1.5 Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.2 South America Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
8.2.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
8.3 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
8.3.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
8.4 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
8.4.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Drugs for Vulvovaginal Candidiasis by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.4 UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.5 Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.1.7 South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)
10 Global Drugs for Vulvovaginal Candidiasis Market Segment by Type
10.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
10.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
10.2 Miconazole Sales Growth and Price
10.2.1 Global Miconazole Sales Growth (2013-2018)
10.2.2 Global Miconazole Price (2013-2018)
10.3 Clotrimazole Sales Growth and Price
10.3.1 Global Clotrimazole Sales Growth (2013-2018)
10.3.2 Global Clotrimazole Price (2013-2018)
10.4 Fluconazole Sales Growth and Price
10.4.1 Global Fluconazole Sales Growth (2013-2018)
10.4.2 Global Fluconazole Price (2013-2018)
10.5 Econazole Sales Growth and Price
10.5.1 Global Econazole Sales Growth (2013-2018)
10.5.2 Global Econazole Price (2013-2018)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2013-2018)
10.6.2 Global Other Price (2013-2018)
11 Global Drugs for Vulvovaginal Candidiasis Market Segment by Application
11.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
11.2 Hospital & Clinic Sales Growth (2013-2018)
11.3 Pharmacy Sales Growth (2013-2018)
12 Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions (2018-2023)
12.2.1 North America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.4 South America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.5 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2018-2023)
12.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
12.3.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
12.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2018-2023)
12.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
12.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

List of Tables and Figures

Figure Drugs for Vulvovaginal Candidiasis Picture
Table Product Specifications of Drugs for Vulvovaginal Candidiasis
Figure Global Drugs for Vulvovaginal Candidiasis CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Drugs for Vulvovaginal Candidiasis CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Types in 2017
Figure Miconazole Picture
Figure Clotrimazole Picture
Figure Fluconazole Picture
Figure Econazole Picture
Figure Other Picture
Figure Drugs for Vulvovaginal Candidiasis Sales Market Share by Applications in 2017
Figure Hospital & Clinic Picture
Figure Pharmacy Picture
Figure United States Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure France Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure UK Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure China Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure India Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Table Bayer Basic Information, Manufacturing Base and Competitors
Table Bayer Drugs for Vulvovaginal Candidiasis Type and Applications
Table Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Perrigo Basic Information, Manufacturing Base and Competitors
Table Perrigo Drugs for Vulvovaginal Candidiasis Type and Applications
Table Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table J & J Basic Information, Manufacturing Base and Competitors
Table J & J Drugs for Vulvovaginal Candidiasis Type and Applications
Table J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Drugs for Vulvovaginal Candidiasis Type and Applications
Table Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Type and Applications
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Effik Basic Information, Manufacturing Base and Competitors
Table Effik Drugs for Vulvovaginal Candidiasis Type and Applications
Table Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Teva Basic Information, Manufacturing Base and Competitors
Table Teva Drugs for Vulvovaginal Candidiasis Type and Applications
Table Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Drugs for Vulvovaginal Candidiasis Type and Applications
Table Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Cisen Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Type and Applications
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Kingyork Group Basic Information, Manufacturing Base and Competitors
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Type and Applications
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2017)
Figure Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2017
Figure Global Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2013
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2017
Figure North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2013
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2013
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table North America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2016
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries 2017
Figure China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table South America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table South America
  • Global and China Drugs for Vulvovaginal Candidiasis Market Research by Company, Type & Application 2013-2025
    Published: 15-Jun-2018        Price: US 2000 Onwards        Pages: 81
    Summary Market Segment as follows: By Type - Miconazole - Clotrimazole - Fluconazole - Econazole - Other By Application - Hospital & Clinic - Pharmacy By Company - Bayer - Perrigo - J & J - Pfizer - Bristol-Myers Squibb - Effik - Teva - Sanofi - Cisen Pharmaceutical - Kingyork Group The main contents of the repo......
  • Global Assisted Reproductive Technology Market Size, Status and Forecast 2025
    Published: 01-Jun-2018        Price: US 3300 Onwards        Pages: 95
    This report studies the global Assisted Reproductive Technology market, analyzes and researches the Assisted Reproductive Technology development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck KGaA - CooperSurgical, Inc. - Vitrolife AB. - Hamilton Thorne, Inc. - Nikon Corporation - Nidacon International AB - Laboratoire CCD - Planer PLC......
  • Global Oral Contraceptive Market Professional Survey Report 2018
    Published: 28-May-2018        Price: US 3500 Onwards        Pages: 103
    This report studies the global Oral Contraceptive market status and forecast, categorizes the global Oral Contraceptive market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Oral Contraceptive market is valued at xx million US$ in 2017 and is expected to reach xx million ......
  • Dysmenorrhea Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 195
    Dysmenorrhea Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Dysmenorrhea Global Clinical Trials Review, H1, 2018" provides an overview of Dysmenorrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Dysmenorrhea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by......
  • Male Hypogonadism Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 228
    Male Hypogonadism Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Male Hypogonadism Global Clinical Trials Review, H1, 2018" provides an overview of Male Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Male Hypogonadism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of diseas......
  • Secondary (Hypogonadotropic) Hypogonadism Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 96
    Secondary (Hypogonadotropic) Hypogonadism Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Secondary (Hypogonadotropic) Hypogonadism Global Clinical Trials Review, H1, 2018" provides an overview of Secondary (Hypogonadotropic) Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Secondary (Hypogonadotropic) Hypogonadism. Report includes an overview of trial numbers and their aver......
  • Peyronies Disease Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 44
    Peyronies Disease Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peyronies Disease Global Clinical Trials Review, H1, 2018" provides an overview of Peyronies Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Peyronies Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of diseas......
  • North America Drugs for Vulvovaginal Candidiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 18-May-2018        Price: US 4480 Onwards        Pages: 101
    The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after ......
  • Global and United States Postmenopausal Vaginal Atrophy Treatment Market Research by Company, Type & Application 2013-2025
    Published: 15-May-2018        Price: US 2000 Onwards        Pages: 91
    Summary Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase. Market Segment as follows: By Type - Creams - Ta......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs